中国生物制药(01177.HK)库莫西利胶囊III期研究取得阳性结果

阿斯达克财经
24 Mar

中国生物制药(01177.HK) 公布,集团自主研发的1类创新药库莫西利胶囊联合氟维司群注射液用于既往未经治疗的激素受体阳性、人表皮生长因子受体2阴性局部晚期或转移性乳腺癌的III期临床试验已完成方案预设的期中分析,独立数据监查委员会判定有效性达到方案预设的优效界值。集团已与中国国家药品监督管理局药品审评中心就该适应症的上市申请进行沟通,并获得同意提交库莫西利联合氟维司群新增该一线乳腺癌适应症的上市申请。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-24 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10